Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Y-3 Injection in Acute Ischemic Stroke
ChiCTR2400088762Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Y-3 40 mg injection qd with Placebo injection qd (2 arms). Primary endpoint: Proportion of subjects with mRS score ≤1 on treatment day 90. Started Aug 2024; status: recruiting.
02
Drugs
loberamisal
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400088762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088762.